What are you actually buying?
Four things, and their relative value determines whether a price is sensible.
An NHS contract, where one exists. This is the asset that cannot readily be replicated, and it accounts for much of why established pharmacies command the prices they do.
A patient base — the prescriptions that arrive without being won. One caution: patient loyalty attaches partly to the departing owner and staff, not wholly to the premises.
Trading history, which supports lending and informs valuation. As this library notes on payments underwriting, it also helps a business obtain the commercial arrangements a new one struggles to secure.
An operating business: staff, systems, procedures and a compliance history. It is an asset where it is good and a liability where it is not.
The fourth is where purchases go wrong. Buy a business with weak records, unresolved inspection findings or procedures that do not reflect practice, and you have bought a remediation project priced as a going concern. The work falls due immediately. The price assumed it would not.
What does starting one give you?
Nothing, except the ability to build it properly. That is worth more than it sounds and less than founders assume.
The genuine advantages are structural. You can build systems, procedures and records to the standard this library describes, rather than retrofit them. That matters, because the inspection data identifies governance as the dominant failure area. You can choose the model deliberately: private, distance-selling or a hybrid. There is no inherited staffing, lease, reputation or regulatory history. And you can size the cost base to the actual business, not the one somebody else ran.
The disadvantages are equally structural. There is no revenue for a period that is usually longer than planned. There is no trading history, which hits lending, acquiring, insurance and supplier terms all at once. Demand must be built — in private services that is a marketing and retention problem, not a dispensing one. And the NHS contract question, covered next, constrains what kind of business you can realistically start at all.
Can you still obtain a new NHS contract?
Rarely, and this single fact shapes the entire market-entry landscape.
Entry to the NHS pharmaceutical services list runs through the pharmaceutical needs assessment framework. An application generally must show it meets a need identified in the relevant assessment, or offers unforeseen benefits. Applications do succeed — but they are not the ordinary route into ownership.
Two consequences follow. First, the price of an existing pharmacy embeds the scarcity of its contract. That is why buying often costs more than the trading figures alone would justify. Second, new entrants are pushed toward models that do not depend on a conventional contract: distance-selling pharmacy and private services. That is precisely the territory this site covers in depth, and it explains why so much of the sector's new entry arrives there.
If you want to open a high street pharmacy, establish the position in your intended area early. It determines whether your plan is a plan or an aspiration.
How are pharmacies valued?
Usually as a multiple of adjusted earnings, with goodwill dominating because the tangible assets are modest. The multiple is a set of judgements about durability, not a formula. The factors that move it are worth understanding from both sides of a transaction.
| Raises the multiple | Lowers it |
|---|---|
| Stable NHS volume with a settled local prescribing base | Volume dependent on one surgery or one prescriber relationship |
| Established private service income with genuine retention | Private income which is recent, promotional or unrepeatable |
| Long lease on sensible terms, or freehold | Short lease, break clauses, or rent above market |
| Staff who will remain, with the business not dependent on the owner | An owner-operator whose departure removes the pharmacist and the relationships |
| Clean regulatory history and records which evidence practice | Unresolved findings, weak documentation, or an inspection due |
The line sellers underestimate, and buyers should press hardest, is the fourth. A pharmacy whose owner is also its only regular pharmacist, and whose patients come because of that person, is selling something that partly leaves with the seller. That should show up in the price, in the handover period, or in both.
What should diligence uncover?
Buyers instruct accountants to check the accounts and solicitors to check the contracts, then look at the regulatory position last or not at all. That inverts the risk. A pharmacy's compliance history bears directly on its future income. An unresolved inspection finding is remediation work with a deadline. A weak record system is a rebuild. A payments relationship secured on inaccurate disclosures is an account that may not survive a change of ownership. A superintendent arrangement that was never properly documented is a problem the buyer inherits on completion. The items to request are unglamorous and specific. Inspection reports and every action arising from them, with evidence of closure. The current procedures, compared against what the team actually does. The near-miss and incident log — its absence is itself a finding. Responsible pharmacist records. Controlled drugs registers and destruction records. Private service documentation, including prescribing arrangements and patient records. And confirmation of what the regulator has been told about ownership and superintendent arrangements. A seller who can produce these quickly is telling you something valuable about the business. A seller who cannot is telling you something more valuable still.
Share purchase or asset purchase?
The distinction carries tax, regulatory, employment and liability consequences. Treat it as a decision, not a default proposed by whoever drafted first.
A share purchase acquires the company itself — history, contracts and liabilities intact. That preserves continuity, but the historic exposure comes too. Arrangements generally stay in place without renegotiation. Warranties and indemnities matter more, because the buyer inherits whatever has not been disclosed.
An asset purchase acquires selected assets and generally leaves historic liabilities with the seller. The cost is reconstituting the position, which touches the regulatory registration, the NHS arrangements, supplier accounts, the lease and employment obligations. It is cleaner on liability and more work on continuity.
Both routes require the regulatory position to be handled properly. Ownership of a registered pharmacy and the superintendent arrangements are matters the GPhC records and expects to be accurate and timely. A transaction that completes commercially before the regulatory steps are in hand has created a gap somebody will have to explain.
What costs do both routes underestimate?
Five, and they apply to buyers and founders alike.
Working capital for stock. For a dispensing business it is substantial, and it is often modelled as an afterthought.
The remediation period after a purchase, when procedures, records and systems are brought up to standard while the business trades.
Professional fees — legal, accountancy and regulatory advice. Pay for these properly, precisely because this is the transaction where economising is most expensive.
The commercial arrangements a new business cannot yet obtain: acquiring terms, supplier credit and insurance priced without trading history. That is a real cost, not an inconvenience.
Owner time. The first year consumes it on matters that produce no revenue. That is why a plan requiring the owner to also dispense full time is usually a plan that fails.
Which route suits which owner?
The honest test is not financial but temperamental. It comes down to which kind of work an owner does well.
Buying suits an owner who improves things. You are comfortable inheriting arrangements and correcting them, you need income from the outset, and you can run or commission proper diligence. It particularly suits a pharmacist who intends to work in the business and wants an existing patient base to build on.
Starting suits an owner with a specific model in view, particularly in private or distance-selling services. You can fund a period without revenue, you accept that demand-building is the actual job, and you value building systems correctly over acquiring them quickly.
The route that suits almost nobody is buying a pharmacy in order to convert it into something entirely different. That buyer pays for an NHS contract and a patient base while planning a business that uses neither — and would often have been better off starting.
What does the first year look like?
For a purchase, the first year is largely about retention and remediation. Patients and staff are deciding whether to stay. Prescriber relationships are being re-established with a new face. Whatever diligence found is being corrected while the business trades. Revenue is there from day one, and so is the work — an owner who planned only for the trading is usually surprised by the rest.
For a start-up, the first year is about proving demand. Revenue arrives slowly. The governance work happens before it produces anything. And the temptation to accelerate through advertising arrives precisely when the operation is least ready to absorb volume — the failure pattern the playbook describes.
Both share one characteristic worth planning for. The first year is when the habits are set. A business that establishes proper records, review cycles and measurement in year one carries that advantage permanently. One that defers them acquires a correction project that gets harder each year it is deferred.
Key takeaways
- Buying acquires an NHS contract, a patient base, trading history and an operating business. The last is where purchases go wrong when compliance is weak.
- Starting acquires nothing except the ability to build properly — which matters, because governance dominates inspection failures. The cost is revenue, history and inherited demand.
- New NHS contracts are difficult to obtain through the pharmaceutical needs assessment framework. That is why new entry concentrates in distance-selling and private models.
- Valuation is a judgement about durability, not a formula. The most underpriced factor is dependence on an owner-operator whose departure removes the pharmacist and the relationships.
- Regulatory diligence is financial diligence. Unresolved findings, weak records and undocumented arrangements are remediation costs with deadlines attached.
- Share and asset purchases carry different liability, tax and continuity consequences. In either case, the regulatory position must be handled properly.
- Buying suits owners who improve things and need income immediately. Starting suits owners with a specific model who can fund the wait. Buying in order to convert suits almost nobody.
Sources and further reading
FAQs
Year one sets the habits.
Whichever route you take, the first year sets the habits — and records are the habit that compounds. Dataforge PMR gives a new business the audit trail a buyer would have paid a premium for. It gives a purchaser somewhere to rebuild one when diligence found it missing.
See Dataforge PMR